This inventor holds 1 USPTO granted patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Shigemitsu Imai: Innovator in Urological Therapeutics
Introduction
Shigemitsu Imai is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for lower urinary tract diseases. His innovative work has led to the creation of a unique compound that holds promise for patients suffering from these conditions.
Latest Patents
Imai holds a patent for an iminopyridine derivative, which is characterized by its selective α-adrenergic receptor antagonistic action. This compound is useful as an agent for the prophylaxis or treatment of lower urinary tract diseases. The patent also includes a screening method for identifying compounds with similar α-adrenergic receptor antagonistic properties. This advancement is crucial for developing effective treatments for patients with bladder outlet obstruction.
Career Highlights
Shigemitsu Imai is currently associated with Takeda Pharmaceutical Company Limited, a leading global pharmaceutical company. His work at Takeda has allowed him to collaborate with other talented professionals in the field, enhancing the impact of his research and innovations.
Collaborations
Imai has worked alongside esteemed colleagues such as Masato Yoshida and Yasuhisa Kohara. Their combined expertise has contributed to the advancement of therapeutic options in urology.
Conclusion
Shigemitsu Imai's contributions to pharmaceutical innovations, particularly in the treatment of lower urinary tract diseases, highlight his role as a key inventor in the field. His patented iminopyridine derivative represents a significant step forward in urological therapeutics.